PIM1 and posterior cortical atrophy: The first-generation PIM-1 antagonist SGI-1776 displayed cardiotoxicity (NCT00848601); however, a second-generation PIM inhibitor, TP-3654 (SGI-9481), exhibited decreased cardiotoxicity and improved potency. Successful studies demonstrating the synergy of PI3K116,117 or FLT3 and PIM co-targeting in PCa would favor PIM inhibitors in clinical trials.